-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $576

Benzinga·10/08/2026 14:11:43
Listen to the news
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $570 to $576.